Markets

Guidewire Software, Inc. (NYSE: GWRE), the platform P&C insurers trust to engage, innovate, and grow efficiently, today announced that five specializations have been awarded to three Guidewire PartnerConnect Consulting partners across the Americas (AMER), Asia Pacific (APAC), and Europe, Middle East and Africa (EMEA) regions. The following PartnerConnect Global Premier Consulting partners have been awarded specializations in the fourth quarter of Guidewire’s fiscal year 2020, for the following Guidewire products: Deloitte: InsuranceSuite Integration – AMER Hexaware: PolicyCenter – APAC PwC: Digital – AMER; PolicyCenter – APAC; and ClaimCenter – APAC EY: Guidewire Cloud “We would like to extend our congratulations to the PartnerConnect Consulting partners who recently achieved Guidewire specializations,” said Lisa Walsh, vice president, Alliances, Guidewire Software. “We are pleased to reward and recognize these partners for their competency in Guidewire products and solutions and for delivering excellence to our shared insurance customers.” Specializations are both regionally and globally based and require partners to demonstrate skills, knowledge, and competency in a specific Guidewire product, as validated by Guidewire certification achievements. The attainment of specializations enables insurers to have more clarity and insight into which partners have proven capabilities in a region. In addition, partners with specializations

Regulatory News: Ipsen (Euronext: IPN: ADR: IPSEY) today announced that it will share data from the company’s growing Rare Diseases Therapeutic Area portfolio, with seven presentations at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting (September 11-15, 2020). These include the oral presentation of Ipsen’s MOVE trial (during the Novel Therapies for Rare Bone Disease session on Saturday, 12 September [11:00am – 12:15pm ET]), the first and only multicenter Phase III study in fibrodysplasia ossificans progressiva (FOP). The data will be presented by Dr Robert Pignolo, Division of Geriatric Medicine and Gerontology, Department of Internal Medicine, Mayo Clinic, and describes the trial outcomes of the oral investigational therapy palovarotene in reducing new heterotopic ossification (HO) volume in 107 pediatric and adult patients with FOP.1 The MOVE efficacy results were compared with data from untreated patients from Ipsen’s Natural History Study (NHS).2 Safety outcomes from the MOVE trial will also be presented. “Our passion and commitment to understanding rare diseases has driven this research forward and we’re proud to present these data at the ASBMR 2020 Annual Meeting,” said Howard Mayer, M.D., Executive Vice President and Head of Research and Development at Ipsen. “Collaboration is critical with

Schlumberger, IBM and Red Hat, announced today a major collaboration to accelerate digital transformation across the oil and gas industry. The joint initiative will provide global access to Schlumberger’s leading exploration and production (E&P) cloud-based environment and cognitive applications by leveraging IBM’s hybrid cloud technology, built on the Red Hat OpenShift container platform. Collaborative development will initially focus on two key areas: Private, hybrid or multi-cloud deployment of the DELFI* cognitive E&P environment enabled by Red Hat OpenShift to significantly expand access for customers. Delivering the first hybrid cloud implementation of the OSDU™ data platform (the open data platform for the industry). Through the agreement with IBM and Red Hat, Schlumberger has committed to the exclusive use of Red Hat OpenShift. Using the container platform will enable the deployment of applications in the DELFI environment across any infrastructure, from traditional data centers to multiple clouds, including private and public. This new way of hosting will offer the possibility to use multiple cloud providers and will address critical issues for customers, facilitating in-country deployments in compliance with local regulations and data residency requirements. The DELFI environment incorporates cutting-edge data analytics and artificial intelligence, drawing upon multiple data sources, automating

ADC Therapeutics SA (NYSE: ADCT), today gave notice that Morgan Stanley & Co. LLC and BofA Securities, Inc., the lead book-running managers in the Company’s recent initial public offering, are releasing a lock-up restriction with respect to 105,000 common shares held by A.T. Holdings II Sàrl, an affiliate of Peter B. Corr and Stephen Evans-Freke who are members of the Company’s board of directors, as part of a block trade of common shares to HPWH TH AG. Both A.T. Holdings II Sàrl and HPWH TH AG are long-term investors who continue to hold significant interests in the Company and are represented on the Company’s board of directors. The release will take effect on September 10, 2020, and the shares may be sold on or after such date. This press release is not an offer for sale of the securities in the United States or in any other jurisdiction where such offer is prohibited, and such securities may not be offered or sold in the United States absent registration or an exemption from registration under the United States Securities Act of 1933, as amended. About ADC Therapeutics ADC Therapeutics SA (NYSE:ADCT) is a late clinical-stage oncology-focused biotechnology company pioneering

Popular, Inc. (NASDAQ: BPOP) announced today that it has declared the following monthly cash dividend on its outstanding shares of Non-Cumulative Monthly Income Preferred Stock: a monthly cash dividend of $0.132813 per share of 6.375% Non-Cumulative Monthly Income Preferred Stock, 2003 Series A, payable on September 30, 2020 to holders of record as of September 15, 2020. The Corporation also announced the following monthly distributions on its outstanding Trust Preferred Securities: a monthly distribution of $0.139583 per security of 6.700% Cumulative Monthly Income Trust Preferred Securities issued by Popular Capital Trust I, payable on October 1, 2020 to holders of record as of September 15, 2020; and a monthly distribution of $0.127604 per security of 6.125% Cumulative Monthly Income Trust Preferred Securities issued by Popular Capital Trust II, payable on October 1, 2020 to holders of record as of September 15, 2020. About Popular, Inc. Popular, Inc. (NASDAQ: BPOP) is the leading financial institution by both assets and deposits in Puerto Rico and ranks among the top 50 U.S. bank holding companies by assets. Founded in 1893, Banco Popular de Puerto Rico, Popular’s principal subsidiary, provides retail, mortgage and commercial banking services in Puerto Rico and the U.S.

Regulatory News: NANOBIOTIX (Paris:NANO) (Euronext : NANO – ISIN: FR0011341205 – the ‘‘Company’’), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced its half year financial results for the six-month period ended June 30, 2020. These results are represented in the condensed consolidated financial statements as at 30 June, 2020, reviewed by the Supervisory Board and the Executive Board on September 4, 2020 and have been subjected to a limited review by the Company’s statutory auditors. Major milestones achieved during the half-year include: Granted Fast Track designation by the United States Food and Drug Administration (US FDA) for the treatment of the patients with locally advanced head and neck cancer, ineligible for platinum-based chemotherapy Announced positive new data from the phase I dose expansion in locally advanced head and neck cancer Received ‘safe to proceed’ from the FDA for the first phase I trial evaluating NBTXR3 in pancreatic cancer Secured non-dilutive financing of €10M in the form of State-Guaranteed Loans (Prêts Garantis par l’Etat, or PGE in France) Consolidated cash availability of €26.6M as at June 30, 2020 “In the context of the COVID-19 crisis, the first half of 2020 presented a

Sand Grove Capital Management LLP (“Sand Grove”) notes the results of the Extraordinary General Meeting held today to vote on proposed changes to the Board and Nomination Committee of Otello Corporation ASA (“Otello” or the “Company”). Whilst Sand Grove is disappointed that shareholders have in a majority voted against its proposals for the Board of Directors of the Company and the Nomination Committee of the Company, we note that the votes were exceptionally close. Sand Grove’s sole objective was to put in place a Board with the breadth of experience and abilities required to deliver value for all shareholders. We do not believe that this result is a strong endorsement of the current Board of Directors and Nomination Committee. Sand Grove remains committed to changing Otello’s corporate governance for the benefit of all shareholders and will review next steps in the coming days. We anticipate updating all Otello stakeholders in the near term. View source version on businesswire.com: https://www.businesswire.com/news/home/20200904005264/en/

OXFORD, England, Aug. 27, 2020 /PRNewswire/ — Vaccitech Limited, a clinical stage biopharmaceutical company developing T cell induction products for infectious diseases and cancer, announces today that it has received a non-dilutive Government grant to support research with its next-generation technology platform to protect against COVID-19. The grant is part of the UKRI-NIHR COVID-19 rapid response rolling call for proposals with potential to deliver public health impacts within 12 months. Preclinical data indicate Vaccitech’s new platform induces leading antibody and cell-mediated immune responses, two arms of the immune system known to protect against disease, when compared with the adenoviral platforms currently in vaccine trials for COVID-19. The preclinical data informed the decision of UK Research and Innovation (UKRI) and the National Institute for Health Research (NIHR), and other funders including the World Health Organization (WHO), to support Vaccitech’s research efforts. Vaccitech was awarded £155k for the first phase of the project worth up to £2.3m in funding. With the grant proceeds, Vaccitech will complete preclinical studies and manufacture sufficient quantities required to initiate a Phase 1 clinical study of its new COVID-19 vaccine candidate in 2021. Depending on clinical success, the vaccine could be a standalone product candidate and/or could be

Liberty Global (Nasdaq: LBTYA, LBTYB and LBTYK) announced today that UPC Schweiz GmbH, a subsidiary of Liberty Global, is publishing the Offer Prospectus for the previously announced all cash public tender offer for all publicly held shares of Sunrise Communications Group AG (SIX Swiss Exchange: SRCG) at a price of CHF110 per share. The Offer Prospectus is available on www.nationalconnectivitychallenger.ch/#for-investors. The tender offer is expected to launch on September 11, 2020, following the completion of a ten SIX Swiss Exchange trading-day cooling-off period under Swiss takeover law, and is scheduled to expire at 10:00 a.m. Eastern Standard Time (4:00 p.m. Central European Summer Time) on October 8, 2020. After this period (and subject to extensions) and if the minimum acceptance threshold of the valid tender of two-thirds of all Sunrise shares on a fully diluted basis is reached or waived, there will be an additional acceptance period of ten SIX Swiss Exchange trading days. The offer by Liberty Global’s subsidiary, UPC Schweiz GmbH, is also conditioned on other customary offer conditions, including regulatory approvals. Sunrise’s Board of Directors has unanimously recommended that its shareholders accept the offer. freenet AG, Sunrise’s largest shareholder, which holds approximately 24% of Sunrise’s

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that Brian M. Culley, Chief Executive Officer, will be presenting at the LD Micro 500 Virtual Investor Conference on September 1, 2020 at 9:40 am Eastern Time / 6:40 am Pacific Time. Brian M. Culley and Brandi L. Roberts, Chief Financial Officer, will also be participating in the 2020 Solebury Trout Zoomside Chat on September 1, 2020 at 12:00 pm Eastern Time / 9:00 am Pacific Time. The Solebury Trout conference format will consist of fireside chats between participating companies and covering analysts. Lineage management will participate in a fireside chat hosted by Joseph Pantginis, Ph.D., Managing Director, Equity Research, H.C. Wainwright & Co., LLC. Interested investors can access both live presentations on the Events and Presentations section of Lineage’s website and archived presentations will be available for 30 days. Additional videos are available on the Media page of the Lineage website, located at www.lineagecell.com/media/. About Lineage Cell Therapeutics, Inc. Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary